Moderna's stock falls after data shows biotech's RSV vaccine trails ...

Jun 26, 2024 · Moderna's stock was on track for its biggest one-day percentage decline since Dec. 27 of 2022, when it fell 9.5%. The stock is down 12.6% in the month to date, but is still up …

CouponFollow Extension

5%
OFF

Moderna's Stock Falls After Data Shows Biotech's RSV Vaccine Trails ...

2 weeks from now

Jun 26, 2024 · Moderna's stock was on track for its biggest one-day percentage decline since Dec. 27 of 2022, when it fell 9.5%. The stock is down 12.6% in the month to date, but is still up …

morningstar.com

9%
OFF

Moderna’s Stock Falls After Data Shows Biotech’s RSV Vaccine Trails ...

2 weeks from now

Moderna Inc.’s stock fell 9% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.

msn.com

9%
OFF

Moderna Stock Dives After RSV Vaccine Proves Less Effective Than …

2 weeks from now

Jun 26, 2024 · After 18 months, Moderna's RSV vaccine proved 49.9% to 50.3% effective against multiple symptoms of lower respiratory tract disease. In comparison, GSK said its vaccine, …

investors.com

9%
OFF

Moderna (MRNA) Shares Decline On RSV Vaccine Efficacy Data

2 weeks from now

Jun 27, 2024 · An 18-month analysis of follow-up data showed that Moderna’s RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with …

nasdaq.com

7%
OFF

Moderna Shares Slide On Concerns Over Drop In RSV Vaccine

2 weeks from now

Feb 12, 2024 · Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine …

yahoo.com

6%
OFF

Moderna Shares Slide As Longer-term Data Shows Quick Fall In RSV ...

2 weeks from now

Feb 9, 2024 · Moderna shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine.

nasdaq.com

7%
OFF

Moderna Shares Slide On Concerns Over Drop In RSV Vaccine …

2 weeks from now

Feb 9, 2024 · Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine …

reuters.com

11%
OFF

Moderna Shares Decline, RSV Vaccine Efficacy Lags Behind …

2 weeks from now

Jun 26, 2024 · Investing.com - Moderna Inc (NASDAQ:MRNA) experienced an 11% drop on Wednesday after the company disclosed that its respiratory syncytial virus (RSV) vaccine, …

yahoo.com

$10
OFF

Moderna Stock Topples After The FDA Throws A Curveball On Its …

2 weeks from now

May 10, 2024 · He notes Moderna has estimated a $10 billion total addressable market for RSV vaccines. Arexvy and Abrysvo generated $1.5 billion and $890 million, respectively, in their …

investors.com

4%
OFF

Moderna (MRNA) Falls As FDA Extends Review Time For RSV Vaccine

2 weeks from now

May 13, 2024 · Shares of Moderna, Inc. MRNA were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory …

nasdaq.com